Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 0 with minor changes only.

1. Notable

   HIVGP-BCG · Proof-of-Concept Clinical Pharmacology Trial for HIV…HIVGP-BCG · Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix

   Primary completion pushed from Aug 18, 2026 to Jun 18, 2027

   Also in this update: Sponsor changed: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair to Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair; Study completion pushed from Oct 28, 2026 to Oct 28, 2027

   Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair·Early Phase 1· NCT07182838· Registry history of NCT07182838 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

2. Notable

   Drug-SNP · Pharmacogenomics ANDA SNP Clinical Study - Topotecan…Drug-SNP · Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms

   Sponsor changed: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair to Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair

   Also in this update: Primary completion pushed from Sep 18, 2026 to Dec 18, 2026; Study completion pushed from Oct 28, 2026 to Jun 28, 2027

   Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair·Phase 2/3· NCT07145333· Registry history of NCT07145333 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.